Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.

As shown, the OS difference between ARID1A‐loss GC patients with ACT and ARID1A‐loss GC patients without ACT remained highly significant after adjusting for age, TNM classification, grade, and TCGA subtype (TCGA: HR, 0.39, 95% CI, 0.22–0.71, p = 0.002, Table S7 ; ZSHS: HR, 0.07, 95% CI, 0.02–0.21, p < 0.001, Table S8 ).

also in 132,142 other papers